Physician profile
Karley Christopher
NPI 1881321651
$872.82
in general payments reported to CMS, 2019-2025
13 companies · $147 in 2025
The $147 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.76 · 2024: $681 · 2025: $147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $872.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $168.32 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $146.79 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $128.23 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $86.04 | 2024 | Repatha, Evenity, Otezla |
| Novartis Pharmaceuticals Corporation | $72.92 | 2024 | |
| Astellas Pharma US INC | $66.96 | 2024-2025 | Veozah |
| Abbvie INC. | $46.59 | 2023-2024 | |
| Kowa Pharmaceuticals America, INC. | $33.10 | 2024 | Livalo |
| Exact Sciences Corporation | $32.00 | 2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.07 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $24.76 | 2024 | Gemtesa |
| Pfizer INC. | $20.90 | 2024 | |
| Glaxosmithkline, LLC. | $15.14 | 2024 | Bexsero, Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karley Christopher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.